JW (Cayman) Therapeutics Co (FRA:JNY) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JNY JW (Cayman) Therapeutics Co Ltd FRA:JNY
45 GF Score
Price €0.22
GF Value €0.43
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

JW (Cayman) Therapeutics Co Quality Rank Related Terms

FRA:JNY
45GF Score
JW (Cayman) Therapeutics Co Ltd FRA:JNY
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is JW (Cayman) Therapeutics Co (FRA:JNY) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of €0.22 is trading 49.8% below its estimated GF Value™ of €0.43.

Key valuation signals for FRA:JNY:

  • Quality Rank:
  • GF Value™: €0.43 vs. price of €0.22 (49.8% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the FRA:JNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges JWCTF:USA02126:Hong Kong
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
45GF Score

Get the complete analysis for FRA:JNY

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.22
Price
€0.43
GF Value